Health
Lilly Agrees to Buy US Biotech Morphic in $3.2 Billion Deal
- Morphic’s shares soar 76% in pre-market trading in US
- Lilly CEO Dave Ricks has promised more early-stage deals
This article is for subscribers only.
Eli Lilly & Co. agreed to buy U.S. gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some of the proceeds from obesity blockbuster Zepbound into its experimental pipeline.
Lilly will pay $57 a share in cash for Waltham, Massachusetts-based Morphic, or 79% more than the closing price Friday, the companies said in a statement Monday. Morphic’s board recommends that stockholders tender their shares in the offer.